Anhui Kedgene Biotechnology
Main focus: Next generation T cell-based therapies
Company stage: Clinical
Diseases: Solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Anhui, China
Anhui Kedgene Biotechnology develops next generation T cell-based therapies for solid tumour treatment. The company uses CRISPR to knock out PD-1 from its T cell products, in order to optimise efficacy and safety.